免疫療法相關的事業合作 (2014~2020年):交易趨勢,企業,財務資訊
市場調查報告書
商品編碼
939915

免疫療法相關的事業合作 (2014~2020年):交易趨勢,企業,財務資訊

Immunology Collaboration and Licensing Deals 2016-2023

出版日期: | 出版商: Current Partnering | 英文 450+ Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供免疫療法的治療藥開發相關近來 (2014~2020年)的聯盟交易的趨勢相關分析,整體交易形成數量的變化,及財務方面 (付款條件) 的趨勢,主要企業 (共25家公司) 的交易形成的動向,契約條件的趨勢,各適應症 (治療標的)的趨勢等調查,近幾年主要的聯盟交易 (共700件以上)等詳細資訊彙整,為您概述為以下內容。

目錄

摘要整理

第1章 簡介

第2章 免疫療法相關的交易形成的趨勢

  • 簡介
  • 免疫療法相關的交易形成:近幾年趨勢
  • 免疫療法相關的交易形成:各交易類型
  • 免疫療法相關的交易形成:各業界
  • 免疫療法相關的交易形成:各開發階段
  • 免疫療法相關的交易形成:各技術種類
  • 免疫療法相關的交易形成:各適應症

第3章 免疫療法相關的事業合作:財務方面的條件

  • 簡介
  • 免疫療法相關的事業合作披露的財政條件
  • 免疫療法相關的事業合作:交易總額
  • 免疫療法相關的事業合作:預付款金
  • 免疫療法相關的事業合作:階段性付款
  • 免疫療法相關的事業合作:權利金費率

第4章 免疫療法相關的代表性交易

  • 簡介
  • 免疫療法相關的合作最活躍的企業
  • 在免疫療法的領域最活躍的企業:聯盟交易的一覽
  • 免疫療法相關的主要的交易:各契約金額

第5章 免疫療法的契約文件名錄

  • 簡介
  • 免疫療法相關的資本交易趨勢:可閱覽契約文章的交易的況

第6章 免疫療法相關的交易形成:各治療標的

  • 簡介
  • 免疫療法相關的交易形成:各治療標的

附錄

  • 附錄 (1):免疫療法相關的聯盟交易一覽,各企業名 (2014~2020年)
  • 附錄 (2):免疫療法相關的聯盟交易一覽,各交易類型 (2014~2020年)
  • 附錄 (3):免疫療法相關的聯盟交易一覽,各開發階段 (2014~2020年)
  • 附錄 (4):免疫療法相關的聯盟交易一覽,各技術種類 (2014~2020年)
簡介目錄
Product Code: CP2224

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of immunology deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse immunology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

  • Trends in immunology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of immunology deal records covering pharmaceutical and biotechnology
  • The leading immunology deals by value
  • Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse immunology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

  • 2.1. Introduction
  • 2.2. Immunology partnering over the years
  • 2.3. Immunology partnering by deal type
  • 2.4. Immunology partnering by industry sector
  • 2.5. Immunology partnering by stage of development
  • 2.6. Immunology partnering by technology type
  • 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for immunology partnering
  • 3.3. Immunology partnering headline values
  • 3.4. Immunology deal upfront payments
  • 3.5. Immunology deal milestone payments
  • 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in immunology partnering
  • 4.3. List of most active dealmakers in immunology
  • 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

  • 5.1. Introduction
  • 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by immunology therapeutic target
  • Deal directory
  • Deal directory - Immunology deals by company A-Z 2016 to 2023
  • Deal directory - Immunology deals by technology type 2016 to 2023
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Immunology partnering since 2016
  • Figure 2: Immunology partnering by deal type since 2016
  • Figure 3: Immunology partnering by industry sector since 2016
  • Figure 4: Immunology partnering by stage of development since 2016
  • Figure 5: Immunology partnering by technology type since 2016
  • Figure 6: Immunology partnering by indication since 2016
  • Figure 7: Immunology deals with a headline value
  • Figure 8: Immunology deals with upfront payment values
  • Figure 9: Immunology deals with milestone payment
  • Figure 10: Immunology deals with royalty rates
  • Figure 11: Active immunology dealmaking activity since 2016
  • Figure 12: Top immunology deals by value since 2016